Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERCOCET vs ESIMIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception and emotional response. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis and exerting analgesic and antipyretic effects.
Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.
Management of moderate to moderately severe pain (FDA-approved),Off-label: severe pain when other analgesics are inadequate (individualized use)
Hypertension (to lower blood pressure, not for initial therapy)
One tablet (5 mg oxycodone/325 mg acetaminophen) every 6 hours as needed for pain; maximum 12 tablets per day.
5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.
Oxycodone: 3.5–4.5 hours (terminal) in normal renal function; prolonged in hepatic/renal impairment (up to 6–12 hours). Acetaminophen: 2–3 hours (terminal) in overdose, extended with hepatic injury.
2.3 ± 0.4 hours; prolonged in renal impairment (up to 6.5 hours in severe cases).
Oxycodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (noroxycodone, oxymorphone). Acetaminophen: hepatic via glucuronidation (UGT1A1/1A6), sulfation, and minor CYP2E1 oxidation.
Olmesartan: undergoes hepatic ester hydrolysis to active metabolite, not metabolized by CYP450 system. Amlodipine: extensively metabolized in liver via CYP3A4. Hydrochlorothiazide: not significantly metabolized.
Oxycodone: primarily renal (up to 19% as unchanged drug, 50% as noroxycodone and oxymorphone metabolites); about 10% biliary/fecal. Acetaminophen: renal (majority as glucuronide and sulfate conjugates, about 5% unchanged).
Primarily renal (>90% as unchanged drug); biliary/fecal <10%.
Oxycodone: 38–45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10–25% bound to albumin (minimal).
40-50% bound to albumin.
Oxycodone: Vd approximately 2.6 L/kg (extensive tissue distribution). Acetaminophen: Vd approximately 0.9 L/kg (total body water).
1.5-2.0 L/kg; suggests extensive tissue distribution.
Oxycodone: oral bioavailability 60–87% (immediate-release). Acetaminophen: oral bioavailability 85–98% (first-pass metabolism minimal).
Oral: 55-65% due to first-pass metabolism.
GFR >60 m L/min: no adjustment; GFR 30-60 m L/min: dose every 8 hours; GFR <30 m L/min: avoid use or use with extreme caution, consider reducing dose to 50% or extending interval to every 12 hours; not recommended in ESRD.
e GFR 30-89 m L/min: no adjustment. e GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce total daily dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended.
Not FDA-approved for children <18 years; off-label: 0.1-0.2 mg/kg oxycodone (max 5 mg) plus 5-10 mg/kg acetaminophen every 4-6 hours; total acetaminophen not to exceed 75 mg/kg/day or 4 g/day.
Not approved for pediatric use; safety and efficacy not established.
Start with low end of dosing, e.g., 2.5 mg oxycodone/325 mg acetaminophen every 6 hours; monitor renal function and avoid >4 g/day acetaminophen; titrate cautiously due to increased sensitivity and fall risk.
Start at 2.5 mg once daily due to increased sensitivity and risk of adverse effects.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of any dosage (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; CYP3A4 inhibitors or discontinuation of CYP3A4 inducers may cause fatal respiratory depression; concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Discontinue as soon as possible when pregnancy is detected. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; seizures; serotonin syndrome; adrenal insufficiency; hepatotoxicity (acetaminophen); increased risk of pancreatitis (if combined with alcohol); risk of overuse for acetaminophen.
Fetal toxicity (see black box warning),Hypotension in volume-depleted patients,Monitor renal function; may increase serum creatinine and BUN,Electrolyte disturbances (hypokalemia, hyponatremia, hypercalcemia),Exacerbation of angina or acute MI (especially with rapid dose increase of amlodipine),Acute angle-closure glaucoma (with HCTZ),Systemic lupus erythematosus exacerbation (with HCTZ),Metabolic acidosis (with HCTZ),Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min)
Hypersensitivity to oxycodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; severe hepatic impairment (acetaminophen hepatotoxicity risk).
Hypersensitivity to any component,Anuria (due to HCTZ),Concomitant use with aliskiren in patients with diabetes
Avoid alcohol and grapefruit juice. Alcohol can potentiate hepatotoxicity from acetaminophen and CNS depression from oxycodone. Grapefruit juice may increase oxycodone levels, enhancing sedative and respiratory depressant effects. No other significant food interactions.
Food may delay absorption; take on an empty stomach for best results. Avoid acidic beverages (e.g., orange juice) within 30 minutes of dosing. No significant food restrictions but a low-acid diet may help symptom control.
Percocet (oxycodone/acetaminophen) is pregnancy category C prior to 30 weeks gestation and category D after 30 weeks. First trimester: No clear evidence of major malformations, but opioid use may be associated with neural tube defects and gastroschisis. Second trimester: Risk of miscarriage, intrauterine growth restriction. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery. Acetaminophen is considered safe in therapeutic doses but overdose is hepatotoxic to fetus.
Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some retrospective studies. In the second and third trimesters, use may be associated with reduced uterine blood flow and fetal tachycardia; avoid near term due to risk of neonatal irritability. Overall, use only if clearly needed and after first trimester.
Oxycodone is excreted into breast milk; relative infant dose is approximately 1-2% of maternal weight-adjusted dose. M/P ratio (milk/plasma) is about 3.2:1 for oxycodone. Acetaminophen M/P ratio ~1.0. Low levels expected, but monitor infant for sedation and poor feeding. Caution with maternal high doses or prolonged use; avoid if mother is ultra-rapid CYP2D6 metabolizer due to risk of toxicity.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio ~2.5-3.5). It may reduce milk production, especially with chronic use. The relative infant dose is estimated at 2-5% of maternal weight-adjusted dose. Caution is advised; monitor infant for irritability, sleep disturbances, and feeding problems.
During pregnancy, increased plasma volume and hepatic metabolism may require higher doses of oxycodone to achieve analgesic effect. However, due to fetal risks, use lowest effective dose for shortest duration. No specific dose adjustments are validated; clinical response should guide dosing. Acetaminophen dosing remains unchanged but avoid exceeding 3 g/day in pregnancy.
No standard dose adjustments are recommended, but due to increased renal clearance in pregnancy, therapeutic effects may be reduced. Use the lowest effective dose for the shortest duration. Avoid sustained-release formulations in pregnancy due to unpredictable absorption.
Percocet contains oxycodone and acetaminophen; the acetaminophen component limits total daily dosing to avoid hepatotoxicity (max 4 g/day in adults, lower in liver disease or alcohol use). Due to oxycodone, it is a Schedule II controlled substance with high abuse potential. Constipation is a common adverse effect; consider prophylactic bowel regimen (e.g., docusate, senna). Respiratory depression risk is dose-related and increased with concurrent CNS depressants. Use with caution in elderly, renal impairment, or sleep apnea. Tolerance and dependence develop with prolonged use. Taper to discontinue after chronic use. Avoid in patients with known hypersensitivity to opioids or acetaminophen.
ESIMIL (esomeprazole) is a proton pump inhibitor (PPI) used for acid-related disorders. Onset of action is rapid, but maximal acid suppression occurs after 5-7 days. Best taken before breakfast for optimal effect. Avoid co-administration with clopidogrel due to reduced efficacy. Monitor magnesium levels with prolonged use, especially in patients taking diuretics or digoxin. Consider calcium and vitamin D supplementation to mitigate osteoporosis risk.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other sedatives (e.g., benzodiazepines, muscle relaxants) as they increase risk of severe drowsiness and respiratory depression.,Do not drive or operate heavy machinery until you know how this medication affects you; it may cause dizziness or drowsiness.,Do not exceed 4,000 mg of acetaminophen per day from all sources; check over-the-counter medications for acetaminophen content.,Stop taking and seek immediate medical attention if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, abdominal pain.,Common side effects include constipation, nausea, vomiting, and drowsiness. Increase fluid and fiber intake to prevent constipation.,This drug has a high risk of addiction and dependence. Store securely out of reach of others. Do not share with others.,Do not suddenly stop taking after prolonged use; a gradual taper is needed to avoid withdrawal symptoms.,Contact your doctor if pain is not controlled or if you experience signs of allergic reaction (rash, swelling, trouble breathing).
Take this medication 30-60 minutes before a meal, preferably breakfast.,Swallow capsules whole; do not crush or chew.,Do not take with other acid reducers unless directed.,Report symptoms of severe diarrhea, bone pain, or muscle cramps.,Avoid alcohol and spicy foods that may worsen symptoms.,Long-term use may increase risk of fractures; ensure adequate calcium intake.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERCOCET vs ESIMIL, answered by our medical review team.
PERCOCET is a Opioid Analgesic Combination that works by Oxycodone is a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception and emotional response. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis and exerting analgesic and antipyretic effects.. ESIMIL is a Unknown that works by Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERCOCET and ESIMIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERCOCET is: One tablet (5 mg oxycodone/325 mg acetaminophen) every 6 hours as needed for pain; maximum 12 tablets per day.. The standard adult dose of ESIMIL is: 5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERCOCET and ESIMIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERCOCET is classified as Category C. Percocet (oxycodone/acetaminophen) is pregnancy category C prior to 30 weeks gestation and category D after 30 weeks. First trimester: No clear evidence of major malformations, but. ESIMIL is classified as Category C. Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.